Authors

Latest:

Defining Eligibility and Providing Counseling Key for Lung Cancer Screening Programs

Through detailing past programs and discussing how they've each addressed their own challenges, the American Thoracic Society and the American Lung Association's new lung cancer screening guide can help clinicians design, implement, conduct, and streamline lung cancer screening programs.

Vikram C. Gorantla, MD

Latest:

Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Viktor Grünwald, MD, Medical School Hannover

Viktor Grunwald, MD, PhD

Latest:

Dr Grünwald on Tumor Burden Outcomes From the CLEAR Trial in Advanced RCC

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Vinay Gupta, MD

Latest:

Novel Proteasome Inhibitors for Multiple Myeloma

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Vince Calio

Latest:

Novel Antibody-Drug Conjugate Enters Phase III Trial for Metastatic TNBC

Investigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.

Vincent Chung, MD

Latest:

Dr. Chung on Adding Dietary Supplements to Chemotherapy in Pancreatic Cancer

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Vincent J. Picozzi, MD

Latest:

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Vincent Lam, MD

Latest:

Dr Lam on the Tumor Microenvironment in ALK Fusion+ Lung Cancer

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

Vincent Miller, MD

Latest:

Dr. Vincent Miller Describes FoundationOne

Vincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes FoundationOne, a fully informative genomic profile that launched in 2012.

Vincent T. DeVita, Jr., MD

Latest:

Dr. DeVita Discusses "The Death of Cancer"

In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there. In an interview with OncLive hosted by Maurie Markman, MD, he speaks with DeVita on his book and his thoughts on how the field has evolved.

Vincent T. Ho, MD, Dana-Farber Cancer Institute

Vincent Vandecaveye, MD, PhD

Latest:

Dr. Vandecaveye on Diffusion MRI for Tumor Differentiation

Vincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.

Vincent Y. Ng, MD

Latest:

Dr. Ng on Immunotherapy in Micrometastatic High-Risk Soft Tissue Sarcoma

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

Vinod A. Pullarkat, MD

Latest:

Dr. Pullarkat on Treatment Strategies in Transplant Ineligible ALL

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses treatment strategies in transplant ineligible acute lymphoblastic leukemia (ALL).

Vinod Pullarkat, MD, City of Hope Medical Center

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Viola Poeschel, MD

Latest:

Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL

Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.

Viola W. Zhu, MD, PhD

Latest:

Dr. Zhu on TMB in Lung Cancer

Viola W. Zhu, MD, PhD, medical oncologist/hematologist, University of California, Irvine, discusses tumor mutational burden (TMB) in lung cancer.

Vip Viprakasit, MD, DPhil

Latest:

Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-Thalassemia

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Viraj Master, MD, PhD

Latest:

Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.